Academic Journals Database
Disseminating quality controlled scientific knowledge

Treating Locally Advanced, Recurrent or Metastatic Endometrial Cancer: A Focus on Ixabepilone

ADD TO MY LIST
 
Author(s): Kimberly Kilfoyle | Don S Dizon

Journal: European Journal of Clinical & Medical Oncology
ISSN 1759-8958

Volume: 2;
Issue: 2;
Start page: 69;
Date: 2010;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: endometrial cancer | chemotherapy | biologic therapy | clinical trials

ABSTRACT
Endometrial cancer is a common malignancy affecting women. The majority of patients are diagnosed with endometrial cancer early and treated curatively with surgery and adjuvant therapy. The platinums, taxanes, and anthracyclines are the most active agents in endometrial cancer and therefore form the basis of first-line chemotherapy regimens. Challenges arise in the context of women who suffer from disease that is refractory to first-line chemotherapy or recurrent after receiving treatment. Second-line therapies are currently being investigated. The most effective to date is paclitaxel; however, the response is temporary, patients ultimately progress, and survival is poor. Other therapies have failed to show improved response or survival compared with paclitaxel in the second-line setting. Because paclitaxel is part of first-line therapy, there are many patients who are paclitaxel resistant but require second-line therapy. Ixabepilone is a novel semi-synthetic member of the epothilones that acts as a microtubule-stabilizing drug similar to paclitaxel. However, ixabepilone has shown activity in cell lines that are paclitaxel resistant, and has shown activity in clinical trials against a variety of malignancies. Current investigations into ixabepilone for endometrial cancer are ongoing and will further define ixabepilone’s role in treatment for endometrial cancer.
RPA Switzerland

Robotic Process Automation Switzerland

    

Tango Jona
Tangokurs Rapperswil-Jona